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Abstract
AIM: The aim of this study is to validate the accuracy ofHER2 assessment on biopsies by comparingmatched biopsy/
surgical material from the same patients. METHODS: HER2 status was evaluated by immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH) in 103 cases of gastric and gastroesophageal junction cancers in coupled
biopsy and surgical material. RESULT: Complete concordance between IHC and FISH results on biopsy versus surgical
samples was noted in 80% and 95% of cases, respectively. At comprehensive comparison, including IHC and FISH
data on biopsy and surgical samples, 89% of biopsies were predictive of HER2 status in surgical samples, whereas
11% showed variable inconsistencies. The majority of these (10 of 12 cases) showed IHC score 0/1+ on biopsy but
were all IHC positive and amplified at surgery; in particular, three (3 of 35; 8.5%) IHC score 0 and four (4 of 16; 25%)
IHC score 1+ cases were FISH amplified on biopsy material also, whereas the remaining three cases were FISH
non-amplified on biopsy. The percentage of cases, which were FISH amplified with IHC score 1+ or 2+ on biopsies,
were similar (25% and 33%, respectively) and they also shared a similar grade of amplification. These data suggest
that both IHC score 1+ and 2+ on biopsy material represent “equivocal cases” that may merit further investigation.
CONCLUSIONS: The predictive value of HER2 IHC in biopsies is high. FISH analysis should be considered for IHC
score 2+ and 1+ biopsy cases. Approximately 8% of cases will not be accurately predicted by biopsy evaluation.
Translational Oncology (2013) 6, 10–16
Introduction
Despite a slow decrease in incidence, gastric cancer is still one of the
leading causes of cancer-related deaths worldwide [1]. Early-stage car-
cinomas may be cured by surgery alone; however, advanced gastric
carcinoma (GC) or gastroesophageal junction carcinoma (GEJC),
whether resectable or unresectable, still present with a dismal prognosis
[2–4]. New therapeutic regimens and drugs, both in the neoadjuvant
and adjuvant settings, are therefore eagerly awaited.
Gastric cancerogenesis is a multistep process and the understanding of
the molecular events involved is increasing rapidly [5]. HER2, part
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of the epidermal growth factor receptor family, is a proto-oncogene
located on chromosome 17q21 [6], which encodes for a transmembrane
tyrosine-kinase receptor. Its importance was first recognized in breast, as
up to 20% to 25% of cancers show overexpression ofHER2 with prog-
nostic and predictive importance [7,8]. Amplification ofHER2 in gastric
cancer has been reported in the literature since the 1980s [9,10], and
a recent systematic analysis has highlighted its prognostic significance
[11]. However, it is only with the introduction of the anti-HER2 drug
trastuzumab (Herceptin; Hoffmann-La Roche, Basel Switzerland) that
these findings have become of major interest. The studies were con-
ducted mainly on gastric cancer and reportedHER2 overexpression rates
between 8.2% and 53% [12], whereas the percent of positivity ranged
between 20% and 25% in esophageal and junctional adenocarcinomas
[13,14]. In 2010, the Trastuzumab for Gastric Cancer (ToGA) study
[15] evaluated the use of the anti-HER2 drug trastuzumab in combina-
tion with chemotherapy (capecitabine and cisplatin or fluorurouracil and
cisplatin) versus chemotherapy alone. A significant survival advantage was
observed in the trastuzumab group with no significant increase in toxic
side effects; these results led to Food andDrugAdministration (FDA) and
European Medicine Agency (EMEA) approval for the use of anti-HER2
therapy in advanced HER2-positive GC and GEJC [16].
Correct and reproducible evaluation ofHER2 status in GC and GEJC
is essential in the selection of patients who may be candidates for anti-
HER2 therapy. In breast cancer, HER2 evaluation is determined by
immunohistochemistry (IHC) as the first method of choice; in equivocal
cases (IHC score 2+), gene amplification requires confirmation by fluo-
rescence in situ hybridization (FISH) [17]. Whereas IHC method sensi-
tivity and specificity vary greatly depending on the antibody and method
used, FISH is more standardized and less variable and is therefore consid-
ered the gold standard for HER2 status assessment [18]. However, the
HER2 evaluation scoring system for breast carcinoma has been shown
to be poorly applicable in gastric cancer because staining is more heterog-
eneous and incomplete membrane immunoreactivity is more frequent
in the latter [19]. For this reason, a different scoring system for HER2
expression in the stomach has been proposed by Hoffman et al. [20].
In the Western world, approximately half of gastric and junctional
cancer patients are diagnosed when the neoplasm is at an unresectable
stage and these patients are the potential target for trastuzumab therapy
[21]. In such cases, the only available tissue for HER2 testing is either
endoscopic or more rarely laparoscopic biopsies; in both situations, the
tissue sample is generally scanty. It is therefore important to define the
predictive accuracy of endoscopic biopsies in the evaluation of HER2
status when compared with surgical material. Some studies have in-
vestigated the reliability of biopsy material, but none focused on this
specifically and systematically [19,22–24].
This study is aimed at the evaluation of: 1) the concordance between
matched biopsy and surgical samples; 2) the comparison of two differ-
ent commercially available HER2 antibodies; and 3) the comparison
of IHC results with HER2 gene amplification as determined by FISH.
The final goal of the study is therefore to validate the accuracy of
HER2 assessment on endoscopic biopsies by comparing matched
biopsy/surgical material from the same patients.
Materials and Methods
Study Group
All consecutive cases of GC accessioned at the Pathology Unit,
Department of Surgical and Diagnostic Sciences (DISC), University
of Genoa between 2004 and 2009 and all consecutive cases of GEJC
accessioned at the Surgical Pathology and Cytopathology Unit, De-
partment of Medicine (DIMED), University of Padua between 2006
and 2010 were reviewed.
Fifty cases of GC and 53 cases of GEJC were selected. Clinical in-
formation including patient’s age, sex, neoadjuvant therapy, and type
of surgical procedure were obtained from the patient’s medical records.
Twenty-eight patients were female and 75 were male; mean age was
69.5 years (range, 37–90).
Selection criteria included cases with available formalin-fixed and
paraffin-embedded material from paired biopsy and surgical resections
(total or partial gastrectomy or Ivor Lewis resections) in the absence
of previous neoadjuvant therapy. From formalin-fixed and paraffin-
embedded blocks, 4-μm-thick sections were cut and made available
for subsequent analyses.
Pathologic Assessment
All cases were reviewed and reclassified in terms of histotype accord-
ing to World Health Organization (WHO) 2010 [25], Laurén [26],
and Ming [27] classifications, grade, and stage [28].
Two representative samples from the surgical resection specimens
were selected as well as all diagnostic biopsy samples for each patient.
Biopsy number for each case ranged between 2 and 13 samples
(median = 5, total sum of 504 samples). Of these 504 samples, only
302 (60%) contained invasive carcinoma and were therefore avail-
able for HER2 status evaluation. For each selected paraffin block, ten
4-μm serial sections were cut. One section was stained with hematox-
ylin and eosin (H&E) and the others were mounted on SuperFrost Plus
slides and made available for IHC and FISH analysis.
Immunohistochemistry
Two different IHC staining methods using automated staining
devices were used: PATHWAY HER2/neu (4B5) rabbit monoclonal
antibody (Ventana Medical Systems, Tucson, AZ) and Oracle HER2
Bond mouse monoclonal antibody (CB11) (Menarini Diagnostics,
Florence, Italy).
The Ventana PATHWAY HER2/neu was performed at the
University of Genoa using the Ventana BenchMark XT platform
(Ventana Medical Systems), whereas the Menarini antibody test was
performed at the University of Padua using the automated Micro-
systems Bondmax (Leica, Wetzlar, Germany), according to the
manufacturer’s instructions.
Briefly, tissue sections were deparaffinized and rehydrated. After
epitope retrieval, endogenous peroxidase was blocked with 5%
H2O2 for 10 minutes. Sections were then incubated with primary
antibodies against HER2 (as per different protocol) and immuno-
peroxidase reaction was performed according to procedure. The slides
were then counterstained with hematoxylin and coverslipped.
Fluorescence In Situ Hybridization
HER2 copy number was investigated by FISH, using the PathVysion
HER2 DNA Probe Kit (Vysis, Downers Grove, IL). A fluorescence
microscope (Olympus BX61, Hicksville, NY) was used for the evalua-
tion of HER2 gene copy number, and image capture was performed
with CytoVision 3.93 software.
The manufacturer’s instructions were modified to optimize the
technique. In brief, sections were incubated at 56°C overnight, de-
paraffinized in three series of Histoclear, and incubated with two
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series of absolute ethanol. Slides were pretreated with Vysis 1NNaSCN
“pre-treatment solution” in a water bath at 81°C for 28 minutes.
Enzymatic digestion was carried out with 260 mg of Vysis Protease I
for 23 minutes for endoscopic biopsies and 28 minutes for surgical
specimens, both in a water bath at 37°C.
Sections were then dried at room temperature before incubation
with 6 μl of HER2/CEP17 probe mix. The slides and probe were
then denatured at 73°C for 5 minutes and hybridized at 37°C over-
night in a Thermobrite. On the second day, the sections were washed
with Vysis post-hybridization wash buffer 1 (0.4× SSC/0.3% NP-40)
at 73°C for 2 minutes in a water bath and then washed with post-
hybridization wash buffer 2 (2× SSC/0.1% NP-40) for 5 minutes at
room temperature. Each section was dried at room temperature
before using 6 ml of fluorescence 4,6-diamino-2-phenylindole as
nuclear counterstain mounting medium.
FISH analysis was performed on one sample of all surgical resections
and on all biopsy samples. In IHC-positive cases, the sample with the
highest IHC score was chosen. All samples were evaluated with FISH
blindly to IHC score.
Immunohistochemical Evaluation
The new scoring system for HER2 assessment in gastric cancer was
used [15,20,29]. Complete staining of cell membrane was not required
for defining cell positivity, but also incomplete, generally basolateral,
staining was accepted (Figure 1, A–C ). This scoring system is slightly
different if applied to biopsy or surgical specimens and criteria are
given as follows:
Biopsy sample criteria—0, no reactivity in any tumor cell; 1+, faint/
barely perceptible membranous reactivity in at least a cluster of greater
than or equal to five cells; 2+, weak to moderate complete or baso-
lateral membranous reactivity in at least a cluster of greater than or
equal to five cells; 3+, strong complete or basolateral membranous
reactivity in at least a cluster of greater than or equal to five cells.
Surgical specimen criteria—0, no reactivity or membranous reactiv-
ity in less than 10% of cells; 1+, faint/barely perceptible membra-
nous reactivity in ≥10% of cells; 2+, weak to moderate complete
or basolateral membranous reactivity in ≥10% of tumor cells; 3+,
strong complete or basolateral membranous reactivity in ≥10% of
tumor cells.
Figure 1. HER2 IHC scores (PATHWAY HER2/neu 4B5) in biopsy (A–C) and surgical specimens (D–F) and FISH analysis in surgical speci-
mens (G–I) of gastric/gastroesophageal cancer. (A) IHC score 1+—barely perceptible at low magnification (original magnification, ×20).
(B) IHC score 2+—faint at low magnification (original magnification, ×20). (C) IHC score 3+—easily recognizable at low magnification
(original magnification, ×10). (D) IHC score 1+ (original magnification, ×40). (E) IHC score 2+ (original magnification, ×40). (F) IHC
score 3+ (original magnification, ×40). (G) No amplification by FISH. (H) LGA by FISH. (I) HGA by FISH.
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IHC was jointly evaluated by four expert gastrointestinal (GI)
pathologists (L.M., M.F., F.G., and P.C.), and any discrepancies were
resolved by consensus. During evaluation, the area with the highest
IHC positivity in the invasive component was circled so as to facilitate
the identification of the area for FISH analysis.
During IHC evaluation, intratumor heterogeneity was also described
in surgical samples only and cases were considered homogenous
if overexpression was found in more than two thirds of neoplastic
cells [22].
FISH Analysis
All cases were evaluated in a blinded fashion by M.C. following the
American Society of Clinical Oncology/College of American Pathol-
ogists guidelines [17]. Twenty non-overlapping nuclei were counted,
excluding from analysis stromal and inflammatory cells. Cases were
considered not amplified if the HER2/CEP17 ratio was lower than
2 and amplified if the HER2/CEP17 ratio was equal or higher than
2 as previously described [29]. Borderline cases (HER2/CEP17 ratio
between 1.8 and 2.2) were reviewed by L.M. by counting a further
20 tumor nuclei and then assigned to either the amplified or non-
amplified category. Amplified cases were further subdivided into cases
with low-grade amplification (LGA: HER2/CEP17 ratio between 2
and 4) and cases with high-grade amplification (HGA: HER2/
CEP17 ratio >4) (Figure 1, D–F).
Statistical Analysis
Differences of HER2 overexpression in tumors with diverse histo-
logic parameters were analyzed by using the χ2 test.
Differences and correlations between groups were tested with the
modified Kruskal-Wallis non-parametric test for trend. The k coeffi-
cient was used to check the level of agreement between samples of
HER2 staining obtained with 4B5 versus CB11 antibodies and HER2
status established by IHC or FISH. The k values over 0.7 were assumed
to indicate a very good agreement. P < .05 were considered statisti-
cally significant. The statistical analysis was performed using STATA
software (Stata Corporation, College Station, TX).
Fisher exact test and Mann-Whitney U test were used to analyze
patient and tumor characteristics according to HER2 IHC and FISH
status, as specified in Table 3.
Results
Comparison between Different Anti-HER2 Antibodies
(4B5 and CB11)
Excellent agreement between the PATHWAY HER2/neu (4B5)
and the Oracle HER2 Bond IHC system (CB11) methods (see Fig-
ure 2) was observed both in biopsies (agreement 90.3%; k = 0.766;
P < .001) and in surgical samples (agreement 90.3%; k = 0.815;
P < .001).
Because of the excellent agreement between antibodies, and the
already published data concerning the use of 4B5 in gastric cancer
[30], only 4B5 anti-HER2 antibody was considered for all further
statistical analyses.
With both methods, no or only cytoplasmic staining in normal
or metaplastic epithelia, adjacent to neoplasia, was observed; the
latter was disregarded as non-specific. It must be mentioned that this
type of staining did not create problems in the assessment of cell
membrane signal.
Comparison of HER2 Status between Biopsy and
Surgical Samples
Comparison of HER2 status between biopsy and surgical samples
was performed with both IHC and FISH analysis (see Tables 1 and 2).
The concordance rate between IHC and FISH was 99% in sur-
gical samples and 89.9% in biopsies after exclusion of the IHC
score 2+ group, which is known to be “equivocal” [17].
Eighty percent of cases had complete concordance between IHC
results on biopsy and surgical samples (60 IHC 0/1+ cases and 22
IHC 2/3+ cases). Discordance was seen in 20% of cases and spe-
cifically related to 15 cases with IHC 0/1+ on biopsy and IHC 2/3+
on surgical sample, whereas six cases showed the opposite.
Ninety-five percent of cases analyzed had complete concordance
between FISH results on biopsy and surgical samples (71.5% not am-
plified and 23.5% amplified). Conversely, 5% (five cases) showed dis-
cordance in FISH results between biopsy and surgical specimens. In
detail, four cases not amplified on biopsy showed amplification (three
LGA and one HGA) on surgical samples, whereas one case showed
the opposite (HGA on biopsy and no amplification on surgical sample).
Comprehensive Comparison of IHC and FISH Data
between Biopsy and Surgical Samples
A comprehensive comparison was performed including all data on
IHC and FISH analysis in both types of samples, biopsy and surgical.
 In 75 cases (73%), the combined results for IHC and FISH on
biopsy material were on the whole negative (FISH not am-
plified and IHC score 0, 1+, 2+) and all were confirmed on
Figure 2. HER2 status tested by IHC (using two different antibodies)
in biopsy (A) and surgical material (B). The y-axis corresponds to the
number of cases. Note: 4B5, Ventana PATHWAY HER2/neu; CB11,
Menarini Oracle HER2 Bond.
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surgical material. On the basis of these results, such patients
would not have been candidates for anti-HER2 treatment.
 However, 16 cases (16%) were identified in biopsy samples as
being IHC score 3+ (12 cases) or IHC score 2+ and FISH
amplified (4 cases) and confirmed as such on surgical material.
These patients would have been candidates for treatment had
we considered biopsy material only.
 The remaining 12 cases (11%) showed variable inconsistencies
between results on endoscopic biopsies and surgical samples or
between IHC and FISH and were classified as follows:
– Seven cases, IHC score 0 (three cases) or score 1+ (four
cases), were FISH amplified on biopsy material and this
finding was confirmed on the surgical specimen that showed
both IHC positivity (2+, 3+) and amplification by FISH.
– Three cases were FISH non-amplified on biopsy samples
and IHC staining ranged between 0 and score 2+; how-
ever, all three cases were amplified on surgical samples (all
LGA) and IHC positive (score 2+ or 3+).
– One case was IHC score 0 but LGA by FISH on biopsy
material; similarly, surgical sample evaluation showed LGA
by FISH in the absence of immunoreactivity with IHC.
– One case was FISH amplified (HGA) on biopsy material
with IHC score of 3+; however, there was no immuno-
reactivity or FISH amplification on either block of the
surgical specimen.
Intratumor Heterogeneity in HER2 Staining
In surgical samples, 49 cases were completely negative (score 0) for
HER2. Of the 54 cases that showed immunostaining (IHC score 1+,
2+, or 3+), only 13 (24%) showed homogenous expression and all of
these scored 3+. Given the known intratumor heterogeneity [19], dif-
ferences in two separate surgical paraffin blocks were also checked.
Complete correspondence between blocks was seen in 87 cases
(84.5%) of which 66 were negative (scores 0 or 1+), 12 were highly
positive (score 3+), and 9 scored 2+. In the remaining 16 cases
(15.5%), comparison between blocks provided different results. Par-
ticularly, 11 (10.7%) cases resulted positive (scores 2+ or 3+) in one
block and negative (scores 0 or 1+) in the other.
HER2 versus Clinicopathologic Variables
Clinicopathologic correlations are summarized in Table 3. No sig-
nificant difference was noted in HER2 overexpression or amplification
when compared to tumor site, mean tumor size, differentiation, growth
pattern according to Ming, or stage. Statistically significant differences
were observed only for Laurén classification.
Discussion
In this study, we focused on the comparative evaluation of biopsy and
surgical samples of GC and GEJC in the determination of HER2
status. The majority of previous studies have evaluated the predictive
value of IHC compared to the gold standard FISH, but few authors
have considered identifying the predictive value of biopsy material by
using matched biopsy/surgical samples. The four major studies
[19,22–24] on this topic, dating from 2006 to 2012, report a con-
cordance rate between biopsy and surgical specimens ranging from
88.5% to 96.2% in series composed of matched samples (from 12
to 200 cases in different case series). These rates of concordance are
on the whole similar to our study. However, several major meth-
odological differences with our study must be highlighted: 1) only
intestinal type gastric cancers or only gastric cancers were considered
[19,24]; 2) the IHC evaluation score used had not yet been modified
for gastric cancer [24]; 3) FISH analysis on matched biopsies was
applied only to a subset of cases that had demonstrated amplification
on the surgical specimens [24]; 4) no focus was made on the predictive
role of biopsy in HER2 status evaluation [19,23].
In our study, matched biopsy/surgical samples show a better
concordance rate for FISH amplification (95%) with respect to IHC
(80%). The lower concordance rate in IHC is mostly dependent on
a relevant number of patients (15 cases) who were underscored
on biopsy samples (IHC score 0/1+) versus surgical sample (IHC
score 2+/3+). For therapeutic purposes, these patients (with IHC
score 0/1+) should not be tested further with FISH and are excluded
from anti-HER2 therapy assignment. However, when evaluating their
surgical specimens, they turned IHC score 2+/3+ and therefore would
have undergone further evaluation by FISH (score 2+) or would have
been treated directly (score 3+). The percentage of these cases that we
can identify by applying FISH analysis on all biopsies corresponds to
8.5% of IHC score 0 and 25% of IHC score 1+: this latter value is
not dissimilar to IHC score 2+ biopsies with amplification (33%).
Similar results were also shown in the ToGA screening program, where
23% of IHC score 0/1+ and 26% of IHC score 2+ were amplified
[31]. Whereas IHC evaluation has been modified in GC/GEJC
[20], the flowchart to FISH analysis of IHC score 2+ cases remains
unvaried with respect to breast cancer, in which 36% of IHC score 2
“equivocal” cases are FISH amplified [15,32]. However, ToGA trial
[31] post-hoc analysis has shown that trastuzumab plus chemotherapy
substantially improved overall survival in patients with high expression
of HER2 (i.e., IHC score 2+ and amplification or IHC score 3+)
compared with patients with low expression of HER2 protein (i.e.,
IHC score 0 or 1+ with FISH amplification). In this post-hoc analysis,
cases were subdivided on the basis of IHC scores following the flow-
chart used for breast cancer (IHC score 0 or 1+ considered as “negative”
and IHC score 2+ or 3+ considered as “positive”). Our findings on
Table 1. Concordance of HER2 Status Tested by IHC (PATHWAY HER2/neu 4B5) in Biopsy
and Surgical Samples.
Biopsy Samples Surgical Samples NPV (%) PPV (%)
IHC 0 to 1+ IHC 2+ to 3+ Total
IHC 0 to 1+ 60 15 75 80 –
IHC 2+ to 3+ 6 22 28 – 78.6
Total 66 37 103
Concordance rate (%) 90.9 59.5 80%
IHC, IHC staining performed with PATHWAY HER2/neu (4B5); NPV, negative predictive value;
PPV, positive predictive value.
Table 2. Concordance of HER2 Status Tested by FISH in Biopsy and Surgical Samples.
Biopsy Samples Surgical Samples NPV (%) PPV (%)
FISH NA FISH A Total
FISH NA 75 4 79 94.9 –
FISH A 1 23 24 – 95.8
Total 76 27 103
Concordance rate (%) 98.7 85.2 95%
FISH NA, percentage of cases that were not amplified on FISH; FISH A, percentage of cases that
were amplified on FISH; NPV, negative predictive value; PPV, positive predictive value.
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biopsy samples suggest that both IHC score 2+ and 1+ should be con-
sidered “equivocal” and both may benefit from FISH analysis. Indeed,
further demonstration of the similarities between these two groups is
that both show analogous types of amplification (three LGA and one
HGA in both groups). Patients with IHC score 1+ and FISH amplifi-
cation may not differ so substantially from patients with IHC score 2+
and FISH amplification in terms of therapy response. At the moment,
this is still a gray zone that will need to be addressed by specifically de-
signed prospective trials. Indeed, the different overall survivals demon-
strated by ToGA trial for subgroups with low and high levels of HER2
could be explained by a leading effect of cases with IHC score 0 and
IHC score 3+ on IHC score 1+ and 2+ cases. Conversely, when FISH
was applied to IHC score 0/1+ surgical specimens, where a greater
quantity of neoplastic cells are available, only 1 of 66 cases showed
amplification (LGA).
Similarly to ToGA [31], which reports an 87.5% concordance rate
between IHC and FISH on biopsies, we found 89.9% concordance
rate. In contrast, concordance on surgical specimen was much higher
(99%), similarly to results reported by Yang et al. [19]. If we exclude
from the concordance evaluation on biopsies both IHC score 2+
and 1+, then the concordance rate increases to 93.2%. This further
substantiates the concept that IHC score 1+ on biopsies should be
considered as “equivocal.”
The most probable reason for discordance is intratumor hetero-
geneity of HER2 status in GC/GEJC [20,33,34]. Many studies have
commented on this finding; however, few have given a precise defini-
tion. We evaluated heterogeneity as described by Lee et al. [23] and
further investigated the differences in HER2 expression between dif-
ferent blocks of the same surgical specimen. In our study, only 24%
of IHC-positive cases (that is, all IHC score 3+) showed fully homog-
enous expression. All other IHC-positive cases (score 1+ and score 2+)
showed heterogeneous expression with leopard-spot positivity irre-
spective of site (superficial vs deep tumor part). These findings have
also been described by Kim et al. [35]. Extensive biopsy sampling
could minimize this problem. However, as underlined by Lee et al.
[23], no formal recommendations on the number of endoscopic bi-
opsies required for HER2 testing have been as yet proposed, but
endoscopists should be encouraged to sample extensively especially in
advanced GC/GEJC.
With regard to performance between different antibodies, we found
no substantial differences between the PATHWAY HER2/neu (4B5)
and the OracleHER2 Bond IHC system (CB11). Similar findings have
been reported by a recent paper, in which four different antibodies
were compared [36], even though this group found a lower sensitivity
for CB11 compared with the other tested antibodies.
In conclusion, the present study shows that the predictive value of
IHC in biopsies with regard to HER2 assessment is high but probably
dependent on HER2 heterogeneity in GC/GEJC. Our findings sup-
port the concept that FISH analysis should be considered for both
IHC score 2+ and 1+ biopsy cases, and such an approach also solves
the problem of no easy distinction between “faint” and “weak” stain-
ing in practice. Even with this recommendation, approximately 8%
of cases will not be accurately predicted (both underestimation and
overestimation) by biopsy evaluation.
Table 3. Patient and Tumor Characteristics Stratified by HER2 Status Tested by FISH and IHC (PATHWAY HER2/neu 4B5) in Surgical Specimens.
Clinicopathologic Variable HER2 FISH− HER2 FISH+ P IIC 0/1+ IIC 2+/3+ P
Male sex 52/76 (68) 23/27 (85) .051* 44/66 (67) 31/37 (84) .032*
Mean age ± SD, years (n = 103) 69.5 ± 11.2 69.5 ± 10.6 .409† 70.1 ± 10.2 68.5 ± 12.3 .682†
Tumor location .236* .162*
Distal stomach 35/76 (46) 10/27 (37) 29/66 (44) 16/37 (43)
Proximal stomach 4/76 (5) 1/27 (4) 3/66 (5) 2/37 (6)
GEJ/distal esophagus 37/76 (49) 16/27 (59) 34/66 (51) 19/37 (51)
Mean tumor size ± SD, cm 5.8 ± 3.2 4.7 ± 1.8 .164† 5.8 ± 3.2 4.9 ± 2.1 .157†
Lauren histotype .038* .028*
Intestinal 61/76 (80) 26/27 (96) 52/66 (79) 35/37 (95)
Diffuse 15/76 (20) 1/27 (4) 14/66 (21) 2/37 (5)
Ming histotype .658* .834*
Expanding 32/76 (42) 10/27 (37) 26/66 (39) 16/37 (43)
Infiltrative 44/76 (58) 17/27 (63) 40/66 (61) 21/37 (57)
Tumor grade .059* .131*
Low (G1 or G2) 45/76 (59) 22/27 (81) 39/66 (59) 28/37 (76)
High (G3) 31/76 (41) 5/27 (19) 27/66 (41) 9/37 (24)
Pathologic T stage .618* .115*
T1 6/76 (8) 4/27 (15) 5/66 (8) 5/37 (14)
T2 14/76 (18) 5/27 (18.5) 10/66 (15) 9/37 (24)
T3 30/76 (40) 13/27 (48) 29/66 (44) 14/37 (38)
T4 26/76 (34) 5/27 (18.5) 22/66 (33) 9/37 (24)
Pathologic N stage‡ .806* .821*
N0 21/73 (29) 9/27 (33) 18/63 (29) 12/37 (32)
N1, N2, or N3 52/73 (71) 18/27 (67) 45/63 (71) 25/37 (68)
Pathologic M stage, M1 8/73 (11) 2/27 (7) .729* 7/63 (11) 3/37 (8) 1*
Stage group‡ 1* .837*
I 11/73 (15) 7/27 (26) 9/63 (14) 9/37 (24)
II 20/73 (27) 4/27 (15) 18/63 (29) 6/37 (16)
III 38/73 (52) 13/27 (48) 32/63 (51) 19/37 (52)
IV 4/73 (6) 3/27 (11) 4/63 (6) 3/37 (8)
IIC, IHC score; GEJ, gastroesophageal junction.
Data are given as number/total (percentage).
*Fisher exact test.
†Mann-Whitney U test.
‡Missing data are because of lymph node absence in the surgical specimen (pNx).
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